Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEMENTO: Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06112743Phase 4Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 4, open-label trial of mavacamten in hypertrophic cardiomyopathy (HCM), sponsored by Bristol Myers Squibb. Primary endpoint: Composite of maximum left atrial volume index (LAVI) and left ventricular mass index (LVMI) at 48 weeks. Started Jan 2024; status: active, not recruiting.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT06112743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06112743.